Search results
Author(s):
Nur A Rahmat
,
Gregory YH Lip
Added:
3 years ago
Until recently, the vitamin K antagonist (VKA, e.g. warfarin) class of drugs was the only oral anticoagulant in use. VKAs have important inter- and intra-patient variability, influenced by diet, alcohol and drugs; thus, regular anticoagulation monitoring is necessary. Indeed, VKAs offer their best efficacy and safety when the average time in therapeutic range (TTR) is >65–70 % in a particular…
View more
Author(s):
Farhan Shahid
,
Gregory YH Lip
Added:
3 years ago
Atrial fibrillation (AF) and heart failure (HF) are global epidemics that began more than a century ago, and their association with an ageing general population has brought about an increase in cardiovascular morbidity and rising healthcare costs.1,2 More than 50 % of patients with permanent AF have a concurrent diagnosis of HF and this proportion is expected to rise.3 It is well established that…
View more
Author(s):
Demosthenes G Katritsis
,
Bernard J Gersh
,
A John Camm
Added:
3 years ago
Thrombotic material in atrial fibrillation(AF) usually develops in the left atrial appendage as a result of decreased flow and stasis, possible endothelial dysfunction and a hypercoagulable state as indicated by increased fibrinogen, D-dimer, thromboglobulin and platelet factor 4 levels.1 In the Framingham Heart Study, the percentage of strokes attributable to AF increases steeply from 1.5 % in…
View more
Author(s):
Raffaele De Caterina
Added:
8 years ago
Author(s):
Pepie Tsolka
Added:
3 years ago
Novel oral anticoagulants (NOACs) represent new options for preventing stroke in patients with atrial fibrillation (AF), and have been approved for use in North America and Europe. They carry a 50 % lower risk of intracranial haemorrhage compared with warfarin, no clear interactions with food, fewer interactions with medications and no need for frequent laboratory monitoring and dose adjustments…
View more
Author(s):
Katrina Mountfort
,
Paulus Kirchhof
,
A John Camm
,
et al
Added:
2 years ago
Author(s):
Paulus Kirchhof
Added:
8 years ago
Author(s):
Oliver Plunkett
,
Gregory YH Lip
Added:
3 years ago
The introduction of novel oral anticoagulants (NOACs) has widened the treatment options for oral anticoagulation in stroke prevention in non-valvular atrial fibrillation (AF). Guidelines for the management of non-valvular AF have changed to reflect the emerging evidence of their relative safety and efficacy compared with warfarin (see Table 1).1–6
Download original
NOACs are now licensed for…
View more
Author(s):
Freek WA Verheugt
Added:
8 years ago